Discover how AS1411, a revolutionary DNA aptamer, reprograms leukemia cells through differentiation therapy, offering new hope for AML treatment.
Discover how Cysteine 288 in NPM1c+ leukemia creates a redox-sensitive vulnerability that can be targeted with bortezomib therapy.